+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Active Pharmaceutical Ingredients Market to Rise at 6.50% CAGR 2014-2020 owing to Increasing Drug Master File Filing by Indian Companies

Posted on Jan 04, 2016

A new Transparency Market Research report states that the global active pharmaceuticals ingredients (APIs) market stood at US$119.7 bn in 2014 and is predicted to reach US$185.9 bn by 2020. It is expected to expand at a CAGR of 6.50% from 2014 to 2020. The title of the report is “Active Pharmaceutical Ingredients (API) Market: (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”.

 

Browse the full Active Pharmaceutical Ingredients (API) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 report at https://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

 

As per the report, the APIs market is fuelled by the rising abbreviated new drug applications and the increasing drug master file filing via Indian companies. The prime opportunity seen in the market is the patent expiry of promising biological drugs. On the other hand, factors such as the stringent European Union regulatory policies will impede the growth of the APIs market in the coming years.

 

On the basis of type of manufacturing, the market is segmented into API contract manufacturing and captive or in-house API manufacturing. Amongst these, the segment of captive or in-house API manufacturing is experiencing a rapid decline in the market for APIs owing to its lack of profitability for the manufacturer and rising degree of competition in the market. Pharmaceutical companies are inclined towards API contract manufacturing rather than in-house API manufacturing owing to the increasing costs of research and development and the pressure to maintain low prices of finished goods. Thus, outsourcing of API production is increasingly being preferred by manufacturers.

 

On the basis of type of API, the market is segmented into biological APIs and synthetic chemical APIs. Amongst these, the segment of biological APIs is experiencing the most significant growth rate owing to the huge number of pharmaceutical companies involved in this segment.

 

On the basis of drug type, the APIs market is segmented into generic prescription drugs, branded or innovative prescription drugs, and over-the-counter drugs. Amongst these, the volume rise of generic prescription drugs globally will drive the market in forthcoming years.

 

On the basis of therapeutic area, the market is segmented into oncology drugs, non-steroidal anti-inflammatory drugs, cardiovascular drugs, anti-diabetic drugs, musculoskeletal drugs, central nervous system drugs, and others including antiviral, antibacterial, and antifungal drugs. Amongst these, the segment of oncology APIs is anticipated to be the prime segment of the market for APIs owing to the fact that the majority of the drugs within this segment are high-potency active pharmaceutical ingredients (HPAPIs), due to which this segment is swiftly developing within the market for APIs.

 

On the basis of geography, the APIs market is segmented into Europe, Asia Pacific, North America, and Rest of the World (RoW). Amongst these, North America led the market for APIs owing to the rising utilization of APIs within programs of research and development and drug formulations in the region. This region will maintain its superiority in the coming years owing to the rising preference for generic medicines because of high costs of healthcare. On the other hand, Asia Pacific emerged as the second largest APIs market owing to the presence of a huge number of manufacturers of generic medicines.

 

The chief players dominant in the market are Boehringer Ingelheim Group, Dr. Reddy’s Laboratories, Ltd., Cambrex Corporation, BASF SE, Lonza Group, Hospira, Inc., Mylan, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, and Pfizer, Inc., among others.

 

The global active pharmaceutical ingredients market is segmented as follows:

 

Active Pharmaceutical Ingredients Market, by Type of Manufacturing

  • Captive or In-house API manufacturing
  • API contract manufacturing 

 

Active Pharmaceutical Ingredients Market, by Type of API

  • Synthetic Chemical API
  • Biological API

Active Pharmaceutical Ingredients Market, by Type of Drug

  • Branded or Innovative Prescription Drugs
  • Generic Prescription Drugs
  • Over-the-counter Drugs

 

Active Pharmaceutical Ingredients Market, by Therapeutic Area

  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Oncology Drugs
  • Anti-diabetic Drugs
  • Cardiovascular Drugs
  • Central Nervous System Drugs
  • Musculoskeletal Drugs
  • Other Drugs (antibacterial, antiviral, antifungal, etc.)

 

Active Pharmaceutical Ingredients Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

 

About Us

 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

 

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

 

Contact

 

Mr.Sudip S 
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Back To Top